Comparison
Cagrilintide vs. Selank
Two peptides side-by-side — identity, evidence base, legal status and known adverse events.
Identity
Category
Metabolic
Research other
CAS no.
1415456-99-3
129954-34-3
Molecular weight
4253.7 g/mol
751.85 g/mol
Half-life
168 h
0.3 h
Sequence
KCNTATCATQRLANFLVRSSNNLGPVLPPTNVGSNTYThr-Lys-Pro-Arg-Pro-Gly-ProMechanism of action
Cagrilintide
Cagrilintide binds amylin receptors (AMY1, AMY3, formed by the calcitonin receptor plus RAMP proteins). Activation delays gastric emptying, inhibits postprandial glucagon secretion and modulates central satiety signalling via area postrema neurons. An acyl modification enables albumin binding and thereby weekly dosing.
Selank
Selank is a glyproline-tuftsin analog. Proposed mechanisms include modulation of the GABAergic system, effects on serotonin bioavailability, and influence on enkephalinases. Animal studies show anxiolytic and neuroprotective markers; a clear receptor target is not established.
Evidence base
Highest evidence
Human RCT
Human trial
Studies
4
4
of which in humans
3
2
Effects recorded
3
3
Open conflicts
0
0
Documented adverse events
1
1